Eikon Therapeutics, Inc.

Eikon Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops treatments for oncology indications and neurological diseases. The company utilizes a proprietary technology platform centered on single-molecule tracking to discover therapies, while also in-licensing external clinical assets. Its oncology pipeline features EIK1001, an immune-stimulating dual agonist for melanoma and lung cancer; EIK1003 and EIK1004, selective PARP1 inhibitors for various solid tumors; and EIK1005, a Werner helicase inhibitor. Because its candidates are experimental, the company has no marketed products or commercial customers, focusing its treatments on patient populations participating in clinical studies.

The company maintains its principal executive offices in Millbrae, California. Operating on an international scale, the organization runs clinical trials across multiple continents, including North America, Europe, Asia, Africa, and Oceania. Its active study locations span numerous countries such as the United States, Australia, Canada, China, South Korea, South Africa, Israel, New Zealand, and more than a dozen European nations, including the United Kingdom, Germany, France, and Spain.

Summary of the business section of Eikon Therapeutics's latest annual report, written by StockData.